Kubo Hiroshi
Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, 2-1 Seiryoumachi, Aobaku, Sendai 980-8575, Japan.
Gen Thorac Cardiovasc Surg. 2011 Apr;59(4):231-44. doi: 10.1007/s11748-010-0757-x. Epub 2011 Apr 12.
Recent advances have expanded our understanding of lung endogenous stem cells, and this knowledge provides us with new ideas for future regenerative therapy for lung diseases. In studies using animal models for lung regeneration, compensatory lung growth, and lung repair, promising reagents for lung regeneration have been discovered. Stem or progenitor cells are needed for alveolar regeneration, lung growth, and lung repair after injury. Endogenous progenitor cells mainly participate in alveologenesis. However, human lung endogenous progenitor cells have not yet been clearly defined. Recently discovered human alveolar epithelial progenitor cells may give us a new perspective for understanding the pathogenesis of lung diseases. In parallel with such basic research, projects geared toward clinical application are proceeding. Cell therapy using mesenchymal stem cells to treat acute lung injury is one of the promising areas for this research. The creation of bioartificial lungs, which are based on decellularized lungs, is another interesting approach for future clinical applications. Although lungs are the most challenging organ for regenerative medicine, our cumulative knowledge of lung regeneration and of endogenous progenitor cells makes clear the possibilities and limitations of regenerative medicine for lung diseases.
最近的进展拓宽了我们对肺内源性干细胞的认识,这一知识为我们未来治疗肺部疾病的再生疗法提供了新思路。在使用动物模型进行肺再生、肺代偿性生长和肺修复的研究中,已经发现了有前景的肺再生试剂。肺泡再生、肺生长以及损伤后肺修复都需要干细胞或祖细胞。内源性祖细胞主要参与肺泡形成。然而,人类肺内源性祖细胞尚未得到明确界定。最近发现的人类肺泡上皮祖细胞可能为我们理解肺部疾病的发病机制提供新的视角。与此类基础研究同步,面向临床应用的项目也在进行中。使用间充质干细胞治疗急性肺损伤的细胞疗法是该研究中前景广阔的领域之一。基于去细胞肺构建生物人工肺是未来临床应用的另一种有趣方法。尽管肺是再生医学中最具挑战性的器官,但我们对肺再生和内源性祖细胞的累积知识明确了肺部疾病再生医学的可能性和局限性。